Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study aims to compare high-efficiency post-dilution on-line hemodiafiltration and high-flux hemodialysis regarding mortality, hospitalization rate, several clinical and laboratory parameters, and required medications.
The investigators hypothesize that high-efficiency post-dilution on-line hemodiafiltration may provide better outcome, less morbidity, higher quality of life, and lesser requirement of medications.
| Condition | Intervention | Phase |
|---|---|---|
|
End-Stage Renal Disease Hemodialysis |
Procedure: on-line hemodiafiltration Procedure: high flux hemodialysis |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis (TURKISH HDF STUDY) |
- composite of overall mortality and new cardiovascular events to include myocardial infarction, stroke, revascularization, and unstable angina pectoris requiring hospitalization. [ Time Frame: two years ] [ Designated as safety issue: No ]
- cardiovascular mortality [ Time Frame: two years ] [ Designated as safety issue: No ]
- hospitalization rate [ Time Frame: two years ] [ Designated as safety issue: No ]
- intradialytic complications including hypotension and cramp [ Time Frame: two years ] [ Designated as safety issue: No ]
- health-related quality of life, depression burden, cognitive function [ Time Frame: two years ] [ Designated as safety issue: No ]
- required medications [ Time Frame: two years ] [ Designated as safety issue: No ]
- changes in blood pressure, left ventricular geometry, arterial stiffness, post-dialysis body weight, upper mid-arm circumference, hematocrit and related rHu-EPO doses, the levels of phosphorus, albumin, lipid parameters, hsCRP, and β-2 microglobulin [ Time Frame: two years ] [ Designated as safety issue: No ]
- postdialysis total body water determined by bioimpedance analysis [ Time Frame: two years ] [ Designated as safety issue: No ]
| Enrollment: | 782 |
| Study Start Date: | January 2007 |
| Study Completion Date: | March 2010 |
| Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Post-dilution on-line hemodiafiltration
|
Procedure: on-line hemodiafiltration
on-line hemodiafiltration 3 times a week 4 hours
|
|
2
High-flux hemodialysis
|
Procedure: high flux hemodialysis
high flux hemodialysis 3 times a week 4 hours
|
Detailed Description:
The proposed controlled, randomized study aims to compare high-efficiency post-dilution on-line hemodiafiltration and high-flux hemodialysis regarding mortality, hospitalization rate, several clinical and laboratory parameters, and required medications.
Seven hundred and eighty HD patients will be taken into the study. The study will last for two years with an intermediate analysis at the first year. The patients will be randomly placed in two groups:
- Post-dilution on-line hemodiafiltration,
- High-flux hemodialysis.
In both groups, FX series high-flux helixone membranes will be used, duration of each session 240 minutes, and blood flow rates 250-400 ml/min. ONLINEplus integrated Fresenius 4008S machines will be used for on-line post-dilution HDF. Substitution volume will be above 15 liters in hemodiafiltration sessions.
Echocardiography for determination of left ventricular geometry, pulse wave velocity analysis to assess arterial stiffness, evaluation of nutritional and inflammatory state, assessment of life quality, depression and cost analysis will be performed.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- older than 18 years
- on maintenance bicarbonate HD scheduled thrice weekly 12 hours/week,achieved mean single pool Kt/V above 1.2
- willingness to participate in the study with a written informed consent
Exclusion Criteria:
- To be scheduled for living donor renal transplantation
- To have serious life-limiting co-morbid situations, namely active malignancy, active infection, end-stage cardiac, pulmonary, or hepatic disease
- Pregnancy or lactating
- Current requirement for HD more than three times per week due to medical comorbidity
- GFR greater than 10 ml/min/1.73 m2 as measured by the average of urea and creatinine clearances obtained from a urine collection of at least 24 hours
- Use of temporary catheter
- Insufficient vascular access (blood flow rate lower than 250 ml/min)
- Mental incompetence
Contacts and Locations| Turkey | |
| Ege University School of Medicine | |
| Bornova, Izmir, Turkey, 35100 | |
| FMC Clinics Turkey | |
| Adana, Turkey, 01000 | |
| Principal Investigator: | Ercan Ok, MD | Ege University |
More Information
No publications provided
| Responsible Party: | Fresenius Medical Care |
| ClinicalTrials.gov Identifier: | NCT00411177 History of Changes |
| Other Study ID Numbers: | Ege0683 |
| Study First Received: | December 12, 2006 |
| Last Updated: | June 30, 2010 |
| Health Authority: | Turkey: Ministry of Health |
Keywords provided by Ege University:
|
end-stage renal disease hemodialysis cardiovascular morbidity and mortality high flux dialyser on-line hemodiafiltration |
arterial stiffness inflammation life quality left ventricular hypertrophy |
Additional relevant MeSH terms:
|
Kidney Diseases Kidney Failure, Chronic Urologic Diseases Renal Insufficiency, Chronic Renal Insufficiency |
ClinicalTrials.gov processed this record on May 16, 2013